KR20060047776A - Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 - Google Patents
Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 Download PDFInfo
- Publication number
- KR20060047776A KR20060047776A KR1020050039405A KR20050039405A KR20060047776A KR 20060047776 A KR20060047776 A KR 20060047776A KR 1020050039405 A KR1020050039405 A KR 1020050039405A KR 20050039405 A KR20050039405 A KR 20050039405A KR 20060047776 A KR20060047776 A KR 20060047776A
- Authority
- KR
- South Korea
- Prior art keywords
- asthma
- fgf2
- copd
- airway
- ifn
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
Abstract
Description
Claims (20)
- FGF2(Fibroblast Growth Factor-2)를 유효성분으로 포함하는 천식 예방 또는 치료제.
- 제 1항에 있어서, 천식은 IL-13(Interleukin-13)의 과발현에 의해 유발되는 것을 특징으로 하는 천식 예방 또는 치료제.
- 제 1항에 있어서, 천식은 IFN-γ(Interferon-γ)의 과발현에 의해 유발되는 것을 특징으로 하는 천식 예방 또는 치료제.
- 제 1항에 있어서, FGF2는 IL-13의 활성을 억제하는 것을 특징으로 하는 천식 예방 또는 치료제.
- 제 1항에 있어서, FGF2는 혈관내피생성인자(VEGF)의 활성을 억제하는 것을 특징으로 하는 천식 예방 또는 치료제.
- 제 1항에 있어서, FGF2는 TGF-β1 (Transforming Growth Factor-β1)의 활성을 억제하는 것을 특징으로 하는 천식 예방 또는 치료제.
- FGF2(Fibroblast Growth Factor-2)를 유효성분으로 포함하는 만성폐쇄성 폐질환(COPD) 예방 또는 치료제.
- 제 7항에 있어서, 만성폐쇄성 폐질환(COPD)은 IFN-γ(Interferon-γ)의 과발현에 의해 유발되는 것을 특징으로 하는 만성폐쇄성 폐질환(COPD) 예방 또는 치료제.
- 난알부민을 포함하는 알레르겐 및 이중가닥 RNA를 기도 내로 직접 투여하는 것을 포함하는 Th1 천식 또는 만성폐쇄성 폐질환(COPD) 동물모델의 제조방법.
- 제 9항에 있어서, 동물은 마우스인 Th1 천식 또는 만성폐쇄성 폐질환 (COPD) 동물모델의 제조방법.
- 제 9항 또는 제 10항에 있어서, 하기의 단계를 포함하는 Th1 천식 또는 만성폐쇄성 폐질환(COPD) 동물모델의 제조방법:(1) BALB/c 마우스에 5-15㎍의 이중가닥 RNA인 polyinosinic-polycytidylic acid 및 50-100 ㎍의 난알부민을 4번 비강으로 투여하여 감작하는 단계; 및(2) 10일 후 25-75 ㎍의 난알부민을 비강으로 감작하는 단계.
- 제 11항에 있어서, 단계 (1)의 감작하는 이중가닥 RNA는 10㎍으로 사용되는 Th1 천식 또는 만성폐쇄성 폐질환(COPD) 동물모델의 제조방법.
- 제 11항에 있어서, 단계 (1)의 감작하는 난알부민은 75㎍의 난알부민이고, 단계 (2)의 10일 후 50㎍의 난알부민으로 사용되는 Th1 천식 또는 만성폐쇄성 폐질환(COPD) 동물모델의 제조방법.
- 제 9항 내지 제 13항 중 어느 한 항에 있어서, 천식은 비호산구성인 것을 특징으로 하는 Th1 천식 또는 만성폐쇄성 폐질환(COPD) 동물모델의 제조방법.
- 제 9항 내지 제 13항 중 어느 한 항에 따라 제조된 Th1 천식 또는 만성폐쇄성 폐질환(COPD) 동물모델.
- 제 15항에 있어서, 동물은 마우스인 Th1 천식 또는 만성폐쇄성 폐질환 (COPD) 동물모델.
- FGF2 (Fibroblast Growth Factor-2)를 유효성분으로 포함하는 IL-13 활성 억제제.
- FGF2 (Fibroblast Growth Factor-2)를 유효성분으로 포함하는 VEGF 활성 억제제.
- FGF2 (Fibroblast Growth Factor-2)를 유효성분으로 포함하는 TGF-β1 활성 억제제.
- FGF2(Fibroblast Growth Factor-2)를 유효성분으로 포함하는 기도섬유화(fibrosis), 기도염증, 기도과민성 또는 기도개형 억제제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0511030-0A BRPI0511030A2 (pt) | 2004-05-12 | 2005-05-12 | agente compreendendo fgf2 como um ingrediente efetivo para tratamento ou prevenção de asma e doença pulmonar obstrutiva crÈnica |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040033261 | 2004-05-12 | ||
KR20040033261 | 2004-05-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070096662A Division KR20070112086A (ko) | 2004-05-12 | 2007-09-21 | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060047776A true KR20060047776A (ko) | 2006-05-18 |
KR100785969B1 KR100785969B1 (ko) | 2007-12-14 |
Family
ID=35320043
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050039405A KR100785969B1 (ko) | 2004-05-12 | 2005-05-11 | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
KR1020070096662A KR20070112086A (ko) | 2004-05-12 | 2007-09-21 | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
KR1020090063996A KR20090114341A (ko) | 2004-05-12 | 2009-07-14 | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성 폐질환 예방 또는 치료제 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070096662A KR20070112086A (ko) | 2004-05-12 | 2007-09-21 | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 |
KR1020090063996A KR20090114341A (ko) | 2004-05-12 | 2009-07-14 | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성 폐질환 예방 또는 치료제 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8030274B2 (ko) |
EP (1) | EP1773374A4 (ko) |
JP (1) | JP4669512B2 (ko) |
KR (3) | KR100785969B1 (ko) |
CN (1) | CN1953765B (ko) |
AU (1) | AU2005239957B2 (ko) |
BR (1) | BRPI0511030A2 (ko) |
CA (1) | CA2566400A1 (ko) |
MX (1) | MXPA06013025A (ko) |
NZ (1) | NZ551950A (ko) |
RU (1) | RU2351356C2 (ko) |
WO (1) | WO2005107794A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009028917A1 (en) * | 2007-08-31 | 2009-03-05 | Dong-A Pharm.Co., Ltd. | Formulation for inhalation comprising fibroblast growth factor-2 as an effective ingredient for treatment or prevention of asthma and/or chronic obstructive pulmonary disease |
KR20160003269A (ko) * | 2008-03-28 | 2016-01-08 | 주식회사 라보 쥬48576;사 | 피부의 노화 치료제 |
KR20200012587A (ko) * | 2018-07-27 | 2020-02-05 | 강원대학교산학협력단 | PTD―bFGF 또는 PTD―bFGF에 의해 생성이 증가된 엑소좀을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008308697A1 (en) * | 2007-10-01 | 2009-04-09 | Anticancer, Inc. | Imageable rodent model of asthma |
JP5513620B2 (ja) * | 2009-08-31 | 2014-06-04 | ポステック・アカデミー‐インダストリー・ファウンデーション | 血管内皮細胞成長因子受容体の阻害によるTh17炎症疾患治療方法およびこのための薬学的組成物 |
KR101427290B1 (ko) | 2012-03-22 | 2014-08-06 | 경희대학교 산학협력단 | 죽여 추출물을 유효성분으로 함유하는 만성폐쇄성 폐질환 예방 및 치료용 약학적 조성물 |
WO2015017949A1 (zh) * | 2013-08-09 | 2015-02-12 | 中国人民解放军军事医学科学院微生物流行病研究所 | 成纤维细胞生长因子2的新用途 |
CN106110301A (zh) * | 2016-07-17 | 2016-11-16 | 李静 | 一种改进的治疗哮喘和慢性阻塞性肺病的药物 |
SG11202001909TA (en) * | 2017-09-15 | 2020-04-29 | Cynata Therapeutics Ltd | Method for treating allergic airways disease (aad)/ asthma |
KR102301000B1 (ko) | 2018-12-10 | 2021-09-15 | (의료)길의료재단 | 5-하이드록시메틸-2-푸르알데히드 비스(5-포르밀푸르푸릴)아세탈을 포함하는 만성 폐쇄성폐질환 예방 및 치료용 조성물 |
WO2020159243A1 (ko) | 2019-01-30 | 2020-08-06 | 한양대학교 산학협력단 | 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용 |
CN110476880B (zh) * | 2019-08-26 | 2021-12-03 | 安徽理工大学 | 一种矽肺病小鼠模型的制备方法 |
KR102166453B1 (ko) | 2020-02-03 | 2020-10-15 | 중앙대학교 산학협력단 | Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물 |
CN115354020A (zh) * | 2022-08-18 | 2022-11-18 | 江西中洪博元生物技术有限公司 | 大鼠气道平滑肌细胞哮喘模型及其构建方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2108277A1 (en) * | 1992-02-14 | 1993-08-15 | Mitsuru Watanuki | Preparation for the therapy of respiratory tract diseases |
US20030040496A1 (en) | 1994-03-15 | 2003-02-27 | Chandler Lois Ann | Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehicles |
JP3703909B2 (ja) * | 1996-05-27 | 2005-10-05 | 三井造船株式会社 | スプレッダ |
GB0129270D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
US8153141B2 (en) * | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
CN1267151C (zh) | 2003-02-27 | 2006-08-02 | 珠海亿胜生物制药有限公司 | 碱性成纤维细胞生长因子膜剂及其制备方法 |
-
2005
- 2005-05-11 KR KR1020050039405A patent/KR100785969B1/ko active IP Right Grant
- 2005-05-12 AU AU2005239957A patent/AU2005239957B2/en not_active Ceased
- 2005-05-12 EP EP05764757A patent/EP1773374A4/en not_active Withdrawn
- 2005-05-12 CA CA002566400A patent/CA2566400A1/en not_active Abandoned
- 2005-05-12 NZ NZ551950A patent/NZ551950A/en unknown
- 2005-05-12 WO PCT/KR2005/001390 patent/WO2005107794A1/en active Application Filing
- 2005-05-12 CN CN2005800153913A patent/CN1953765B/zh active Active
- 2005-05-12 RU RU2006143763/15A patent/RU2351356C2/ru not_active IP Right Cessation
- 2005-05-12 JP JP2007513067A patent/JP4669512B2/ja active Active
- 2005-05-12 MX MXPA06013025A patent/MXPA06013025A/es not_active Application Discontinuation
- 2005-05-12 BR BRPI0511030-0A patent/BRPI0511030A2/pt not_active IP Right Cessation
- 2005-05-12 US US11/568,896 patent/US8030274B2/en active Active
-
2007
- 2007-09-21 KR KR1020070096662A patent/KR20070112086A/ko not_active Application Discontinuation
-
2009
- 2009-07-14 KR KR1020090063996A patent/KR20090114341A/ko not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009028917A1 (en) * | 2007-08-31 | 2009-03-05 | Dong-A Pharm.Co., Ltd. | Formulation for inhalation comprising fibroblast growth factor-2 as an effective ingredient for treatment or prevention of asthma and/or chronic obstructive pulmonary disease |
KR20160003269A (ko) * | 2008-03-28 | 2016-01-08 | 주식회사 라보 쥬48576;사 | 피부의 노화 치료제 |
KR20200012587A (ko) * | 2018-07-27 | 2020-02-05 | 강원대학교산학협력단 | PTD―bFGF 또는 PTD―bFGF에 의해 생성이 증가된 엑소좀을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
AU2005239957B2 (en) | 2008-10-30 |
US20080172751A1 (en) | 2008-07-17 |
WO2005107794A1 (en) | 2005-11-17 |
CA2566400A1 (en) | 2005-11-17 |
CN1953765A (zh) | 2007-04-25 |
KR20090114341A (ko) | 2009-11-03 |
AU2005239957A1 (en) | 2005-11-17 |
MXPA06013025A (es) | 2007-02-12 |
US8030274B2 (en) | 2011-10-04 |
RU2351356C2 (ru) | 2009-04-10 |
BRPI0511030A2 (pt) | 2009-09-29 |
EP1773374A1 (en) | 2007-04-18 |
JP2007537245A (ja) | 2007-12-20 |
NZ551950A (en) | 2009-06-26 |
RU2006143763A (ru) | 2008-06-20 |
KR100785969B1 (ko) | 2007-12-14 |
CN1953765B (zh) | 2011-02-09 |
JP4669512B2 (ja) | 2011-04-13 |
KR20070112086A (ko) | 2007-11-22 |
EP1773374A4 (en) | 2010-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100785969B1 (ko) | Fgf2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제 | |
Sziksz et al. | Fibrosis related inflammatory mediators: role of the IL-10 cytokine family | |
O’Reilly et al. | Interleukin-6, its role in fibrosing conditions | |
Bundschuh et al. | Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. | |
Gonzalo et al. | Mouse eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response | |
Trivedi et al. | Eosinophils in the pathogenesis of allergic airways disease | |
US6846486B1 (en) | Method of treating allergy by administering an anti-histamine antibody | |
Foster et al. | Elemental signals regulating eosinophil accumulation in the lung | |
Coalson | Pathology of bronchopulmonary dysplasia | |
Smart et al. | A plant-based allergy vaccine suppresses experimental asthma via an IFN-γ and CD4+ CD45RBlow T cell-dependent mechanism | |
JP2011162555A (ja) | エアロゾル化抗凝固薬を用いて肺組織におけるフィブリンクロットの形成を防ぐ方法 | |
Kurosaki et al. | AAV6-mediated IL-10 expression in the lung ameliorates bleomycin-induced pulmonary fibrosis in mice | |
EP1736168A1 (en) | Protease inhibitor and preventives or remedies for diseases | |
Mommsen et al. | Productive capacity of alveolar macrophages and pulmonary organ damage after femoral fracture and hemorrhage in IL-6 knockout mice | |
ES2416510T3 (es) | Uso de una citocina capaz de unirse a IL 18BP y de inhibir la actividad de una segunda citocina | |
EP1077723A1 (en) | Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions | |
JP2003513933A (ja) | 喘息治療用インターフェロンガンマ | |
WO2005058234A2 (en) | Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation | |
WO2023222051A1 (zh) | Mif和ripk1在围术期缺血性脑损伤中的应用 | |
CN115282279B (zh) | CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用 | |
JP2004166696A (ja) | Gata−3遺伝子導入アトピー性皮膚炎モデル動物 | |
JP2007295808A (ja) | 気管支喘息発症モデル動物およびその作製方法、並びにその利用 | |
KR20090096688A (ko) | 자가면역 질환의 예방과 치료를 위한 약제의 제조에서 티모신 알파 1의 용도 | |
Pan-CC-Chemokine | Local Blockade of Allergic Airway | |
Tovar et al. | Elidel (Pimecrolimus) Induces Mast Cell Apoptosis in a Murine Model of Urticaria Pigmentosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20121120 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130923 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141105 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151106 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161205 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171011 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 13 |